Tanja is Novotech's Therapeutic Strategy Lead, Oncology, bringing more than 20 years of oncology drug development experience across pharmaceutical, academic, and advisory environments.
Following an academic career as a Research Assistant Professor in immuno-oncology, she held leadership roles in clinical development, medical affairs strategy, and regulatory and commercial functions at leading pharmaceutical companies, including Merck and Takeda.
Tanja has led medical strategy for Keytruda and more than 30 small-molecule, biologic, and cell therapy programs across Phase 1 to Phase 3 development, regulatory filing, and launch. Her regulatory experience includes supporting more than a dozen solid tumor indication submissions and approvals across lines of therapy in more than 40 countries, including the United States, European Union, and Asia. She is recognized for her advisory expertise in cancer drug development and has served as a treatment guidance committee member, invited speaker, reviewer, author, and expert panelist.